Soreide Law Group recently filed a FINRA arbitration for a customer of Laidlaw & Company for losses in several offerings where the firm is advertising through their website that they were the underwriter of the investments. The offerings at issue are contained in the list below but there are many offerings that that they are the underwriter of that investors may own that may be performing poorly or not performing as promised. Some investments below may not have gone down in value, but many alternative investments in this list have. Here is a list of investments LaidLaw & Company is advertising that they were the underwriter of through their investment banking business.
AirLift Investments, LLC
Private-I Partners, LLC
T-Bird Partners, LLC
Bionic Partners, LLC
Shire Investments, LLC
Bluebird Investment Partners
Pre-Game Partners, LLC
Pre-Flight Partners, LLC
Pre-Market Partners, LLC
Social T Partners, LLC
Face-Off Partners II, LLC
Chain-Link Partners, LLC
Face-Off Partners, LLC
Below is a list of common stock offerings that may or may not have declined in value, but many investors who own these could have other investments that lost money:
MEI Pharma
Eleven Biotherapeutics
AIT Therapeutics
Hoth Therapeutics
Affimed (Affi Med)
Gemphire
Athenex, Inc.
Fennec Pharmaceuticals
Cytori Therapeutics
ADMA Biologics
Onconova Therapeutics
Asterias Biotherapeutics
Flexion Therapeutics
Aldeyra Therapeutics
MabVax Therapeutics, Inc.
Repros Therapeutics
Biosig Technologies
Therapix Biosciences
Alliqua
Actinium Pharmaceuticals, Inc.
Relmada Therapeutics
Boston Therapeutics
Cyclacel Pharmaceuticals
NovaBay Pharmaceuticals
Protea Biosciences Group, Inc.
Cel-Sci Corporation
If you invested in any of the aforementioned investments call the securities lawyers at Soreide Law Group for a free consultation to see if you may have a potential claims against Laidlaw & Company for selling unsuitable investments. Call (888) 760-6552.
Steven Graham (CRD 1977736) denies the allegations in a pending customer claim filed on August 11, 2026. The disclosure names Western International Securities as the firm, and the claim involves corporate bonds. No arbitrator has ruled on it. His BrokerCheck report also lists a settled bond dispute and a federal court matter from earlier years.
A claim filed on September 11, 2024 names Thomas Hamlin (CRD 2208505) over a 10% Senior Unsecured Note in iCap Fund III. Every disclosure on his BrokerCheck report involves an iCap private placement and names Somerset Securities as the firm. Each one settled, and a settlement is not an admission of wrongdoing.
Peter Po's most recent settlement came on June 28, 2026, when a corporate bond claim settled for $40,000. Po (CRD 3106974) appears in several settled customer disputes over corporate and high-yield bonds. The disclosures name NI Advisors or California Securities as the firm, and each matter ended in a settlement, not a finding.
Phone:
Fax: 1-954-760-6553
Email: [email protected]